Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,totalAssets,otherCurrentAssets,retainedEarnings,treasuryStock,cash,totalCurrentLiabilities,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,netReceivables,accountsPayable,otherCurrentLiab,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,issuanceOfStock,changeInCash,totalCashFromOperatingActivities,depreciation,changeToAccountReceivables,otherCashflowsFromFinancingActivities,changeToNetincome,capitalExpenditures,WC,language,region,quoteType,triggerable,quoteSourceName,currency,esgPopulated,tradeable,exchangeDataDelayedBy,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,priceHint,exchange,marketState,market,shortName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,Shares Short 4,Short Ratio 4,Short % of Float 4,Short % of Shares Outstanding 4,Shares Short (prior month ) 4,Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,country,website,maxAge,address1,industry
t0,EMMLF,5497618.0,970686016,14625,,-460071,,-460105,,-418387,-433012,-433012,,-196,,,,34,0,433012,418387,-27059,,-460105,-460105,67136780.0,342752.0,5497618.0,5840370.0,1186.0,-70395481.0,8756319.0,5761714.0,324226.0,8756319.0,23545.0,5816825.0,38978.0,257772.0,,-124931,-750,2937179,3000989,90673,2785887,-214353,1260,76516,-26863,292908,-750,5492599.0,en-US,US,EQUITY,False,Delayed Quote,USD,False,False,0,0.013400003,0.19648099,0.0682 - 0.22,-0.13839999,-0.62909085,0.0682,0.22,0.0,0.0816 - 0.0816,0.0816,finmb_45535051,Other OTC,OKYO Pharma Limited,GBP,1727,0,0.08479445,-0.0031944439,-0.037672795,0.094582625,-0.012982622,-0.13726223,96217008,15,America/New_York,EDT,-14400000,4,PNK,REGULAR,us_market,OKYO PHARMA LTD,0.0816,1628526435,0.0,0.0826,0.0816,0.0816,500,0.03,,,0.22,0.0682,0.0848,0.0946,1.73k,,970.69M,,644.61M,56.83%,0.00%,,,,,,,,,,,0.00%,,,,,"Mar 30, 2020","Sep 29, 2020",0.00%,0.00%,-16.13%,-30.50%,,,,-799.5k,-817.79k,-814.19k,,,5.76M,0.01,22.52k,0.41,17.94,,-733.48k,-392.38k,Value,W1K 1NA,Healthcare,4,"OKYO Pharma Limited operates as a life sciences and biopharmaceutical company in the United Kingdom. Its pre-clinical development program includes Chemerin for the treatment of ocular inflammation, dry eye disease, and ocular neuropathic pain; and BAM8, a non-opioid analgesic. OKYO Pharma Limited is headquartered in London, the United Kingdom.",London,44 20 7495 2379,United Kingdom,http://www.okyopharma.com,86400,55 Park Lane,Biotechnology
t-1,EMMLF,5497618.0,970686016,14625,,-460071,,-460105,,-418387,-433012,-433012,,-196,,,,34,0,433012,418387,-27059,,-460105,-460105,67136780.0,342752.0,5497618.0,5840370.0,1186.0,-70395481.0,8756319.0,5761714.0,324226.0,8756319.0,23545.0,5816825.0,38978.0,257772.0,,-124931,-750,2937179,3000989,90673,2785887,-214353,1260,76516,-26863,292908,-750,5492599.0,en-US,US,EQUITY,False,Delayed Quote,USD,False,False,0,0.013400003,0.19648099,0.0682 - 0.22,-0.13839999,-0.62909085,0.0682,0.22,0.0,0.0816 - 0.0816,0.0816,finmb_45535051,Other OTC,OKYO Pharma Limited,GBP,1727,0,0.08479445,-0.0031944439,-0.037672795,0.094582625,-0.012982622,-0.13726223,96217008,15,America/New_York,EDT,-14400000,4,PNK,REGULAR,us_market,OKYO PHARMA LTD,0.0816,1628526435,0.0,0.0826,0.0816,0.0816,500,0.03,,,0.22,0.0682,0.0848,0.0946,1.73k,,970.69M,,644.61M,56.83%,0.00%,,,,,,,,,,,0.00%,,,,,"Mar 30, 2020","Sep 29, 2020",0.00%,0.00%,-16.13%,-30.50%,,,,-799.5k,-817.79k,-814.19k,,,5.76M,0.01,22.52k,0.41,17.94,,-733.48k,-392.38k,Value,W1K 1NA,Healthcare,4,"OKYO Pharma Limited operates as a life sciences and biopharmaceutical company in the United Kingdom. Its pre-clinical development program includes Chemerin for the treatment of ocular inflammation, dry eye disease, and ocular neuropathic pain; and BAM8, a non-opioid analgesic. OKYO Pharma Limited is headquartered in London, the United Kingdom.",London,44 20 7495 2379,United Kingdom,http://www.okyopharma.com,86400,55 Park Lane,Biotechnology
t-2,EMMLF,-113015.0,970686016,65284,,-201748,,-171748,,-102774,-168058,-168058,,-456,,,,-30000,0,168058,102774,-33690,,-171748,-171748,67518700.0,595958.0,-113015.0,482943.0,,-69424317.0,1792602.0,189941.0,574504.0,1792602.0,24790.0,458153.0,263089.0,479970.0,22556.0,-45301,-750,-2414,187149,189563,67647,-119502,2267,116305,-26863,-21024,-750,-116351.0,en-US,US,EQUITY,False,Delayed Quote,USD,False,False,0,0.013400003,0.19648099,0.0682 - 0.22,-0.13839999,-0.62909085,0.0682,0.22,0.0,0.0816 - 0.0816,0.0816,finmb_45535051,Other OTC,OKYO Pharma Limited,GBP,1727,0,0.08479445,-0.0031944439,-0.037672795,0.094582625,-0.012982622,-0.13726223,96217008,15,America/New_York,EDT,-14400000,4,PNK,REGULAR,us_market,OKYO PHARMA LTD,0.0816,1628526435,0.0,0.0826,0.0816,0.0816,500,0.03,,,0.22,0.0682,0.0848,0.0946,1.73k,,970.69M,,644.61M,56.83%,0.00%,,,,,,,,,,,0.00%,,,,,"Mar 30, 2020","Sep 29, 2020",0.00%,0.00%,-16.13%,-30.50%,,,,-799.5k,-817.79k,-814.19k,,,5.76M,0.01,22.52k,0.41,17.94,,-733.48k,-392.38k,Value,W1K 1NA,Healthcare,4,"OKYO Pharma Limited operates as a life sciences and biopharmaceutical company in the United Kingdom. Its pre-clinical development program includes Chemerin for the treatment of ocular inflammation, dry eye disease, and ocular neuropathic pain; and BAM8, a non-opioid analgesic. OKYO Pharma Limited is headquartered in London, the United Kingdom.",London,44 20 7495 2379,United Kingdom,http://www.okyopharma.com,86400,55 Park Lane,Biotechnology
t-3,EMMLF,-113015.0,970686016,65284,,-201748,,-171748,,-102774,-168058,-168058,,-456,,,,-30000,0,168058,102774,-33690,,-171748,-171748,67518700.0,595958.0,-113015.0,482943.0,,-69424317.0,1792602.0,189941.0,574504.0,1792602.0,24790.0,458153.0,263089.0,479970.0,22556.0,-45301,-750,-2414,187149,189563,67647,-119502,2267,116305,-26863,-21024,-750,-116351.0,en-US,US,EQUITY,False,Delayed Quote,USD,False,False,0,0.013400003,0.19648099,0.0682 - 0.22,-0.13839999,-0.62909085,0.0682,0.22,0.0,0.0816 - 0.0816,0.0816,finmb_45535051,Other OTC,OKYO Pharma Limited,GBP,1727,0,0.08479445,-0.0031944439,-0.037672795,0.094582625,-0.012982622,-0.13726223,96217008,15,America/New_York,EDT,-14400000,4,PNK,REGULAR,us_market,OKYO PHARMA LTD,0.0816,1628526435,0.0,0.0826,0.0816,0.0816,500,0.03,,,0.22,0.0682,0.0848,0.0946,1.73k,,970.69M,,644.61M,56.83%,0.00%,,,,,,,,,,,0.00%,,,,,"Mar 30, 2020","Sep 29, 2020",0.00%,0.00%,-16.13%,-30.50%,,,,-799.5k,-817.79k,-814.19k,,,5.76M,0.01,22.52k,0.41,17.94,,-733.48k,-392.38k,Value,W1K 1NA,Healthcare,4,"OKYO Pharma Limited operates as a life sciences and biopharmaceutical company in the United Kingdom. Its pre-clinical development program includes Chemerin for the treatment of ocular inflammation, dry eye disease, and ocular neuropathic pain; and BAM8, a non-opioid analgesic. OKYO Pharma Limited is headquartered in London, the United Kingdom.",London,44 20 7495 2379,United Kingdom,http://www.okyopharma.com,86400,55 Park Lane,Biotechnology
